Don B Sanders1, Zhumin Zhang2, Philip M Farrell3, HuiChuan J Lai4. 1. Department of Pediatrics, 705 Riley Hospital Dr, Suite 4270, Riley Hospital for Children, School of Medicine, Indiana University, Indiana, IN 46202, USA. 2. Department of Nutritional Sciences, 1415 Linden Dr, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53706, USA. 3. Department of Pediatrics, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA; Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA. 4. Department of Nutritional Sciences, 1415 Linden Dr, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53706, USA; Department of Pediatrics, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA; Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA. Electronic address: hlai@wisc.edu.
Abstract
BACKGROUND: In children with cystic fibrosis (CF), recovery from growth faltering within 2 years of diagnosis (Responders) is associated with better growth and less lung disease at age 6 years. This study examined whether these benefits are sustained through 12 years of age. METHODS: Longitudinal growth from 76 children with CF enrolled in the Wisconsin CF Neonatal Screening Project was examined and categorized into 5 groups: R12, R6, and R2, representing Responders who maintained growth improvement to age 12, 6, and 2 years, respectively, and I6 and N6, representing Non-responders whose growth did and did not improve during ages 2-6 years, respectively. Lung disease was evaluated by % predicted forced expiratory volume in one second (FEV1) and chest radiograph (CXR) scores. RESULTS: Sixty-two percent were Responders. Within this group, 47% were R12, 28% were R6, and 25% were R2. Among Non-responders, 76% were N6. CF children with meconium ileus (MI) had worse lung function and CXR scores compared to other CF children. Among 53 children with pancreatic insufficiency without MI, R12 had significantly better FEV1 (97-99% predicted) and CXR scores during ages 6-12 years than N6 (89-93% predicted). Both R6 and R2 experienced a decline in FEV1 by ages 10-12 years. CONCLUSIONS: Early growth recovery in CF is critical, as malnutrition during infancy tends to persist and catch-up growth after age 2 years is difficult. The longer adequate growth was maintained after early growth recovery, the better the pulmonary outcomes at age 12 years.
BACKGROUND: In children with cystic fibrosis (CF), recovery from growth faltering within 2 years of diagnosis (Responders) is associated with better growth and less lung disease at age 6 years. This study examined whether these benefits are sustained through 12 years of age. METHODS: Longitudinal growth from 76 children with CF enrolled in the Wisconsin CF Neonatal Screening Project was examined and categorized into 5 groups: R12, R6, and R2, representing Responders who maintained growth improvement to age 12, 6, and 2 years, respectively, and I6 and N6, representing Non-responders whose growth did and did not improve during ages 2-6 years, respectively. Lung disease was evaluated by % predicted forced expiratory volume in one second (FEV1) and chest radiograph (CXR) scores. RESULTS: Sixty-two percent were Responders. Within this group, 47% were R12, 28% were R6, and 25% were R2. Among Non-responders, 76% were N6. CF children with meconium ileus (MI) had worse lung function and CXR scores compared to other CF children. Among 53 children with pancreatic insufficiency without MI, R12 had significantly better FEV1 (97-99% predicted) and CXR scores during ages 6-12 years than N6 (89-93% predicted). Both R6 and R2 experienced a decline in FEV1 by ages 10-12 years. CONCLUSIONS: Early growth recovery in CF is critical, as malnutrition during infancy tends to persist and catch-up growth after age 2 years is difficult. The longer adequate growth was maintained after early growth recovery, the better the pulmonary outcomes at age 12 years.
Authors: Michael W Konstan; Wayne J Morgan; Steven M Butler; David J Pasta; Marcia L Craib; Stefanie J Silva; Dennis C Stokes; Mary Ellen B Wohl; Jeffrey S Wagener; Warren E Regelmann; Charles A Johnson Journal: J Pediatr Date: 2007-06-22 Impact factor: 4.406
Authors: P M Farrell; M R Kosorok; A Laxova; G Shen; R E Koscik; W T Bruns; M Splaingard; E H Mischler Journal: N Engl J Med Date: 1997-10-02 Impact factor: 91.245
Authors: Philip M Farrell; Zhanhai Li; Michael R Kosorok; Anita Laxova; Christopher G Green; Jannette Collins; Hui-Chuan Lai; Linda M Makholm; Michael J Rock; Mark L Splaingard Journal: Pediatr Pulmonol Date: 2003-09
Authors: M S Marcus; S A Sondel; P M Farrell; A Laxova; P M Carey; R Langhough; E H Mischler Journal: Am J Clin Nutr Date: 1991-09 Impact factor: 7.045
Authors: Don B Sanders; Zhanhai Li; Anita Laxova; Michael J Rock; Hara Levy; Jannette Collins; Claude Ferec; Philip M Farrell Journal: Ann Am Thorac Soc Date: 2014-01
Authors: Drucy Borowitz; Karen A Robinson; Margaret Rosenfeld; Stephanie D Davis; Kathryn A Sabadosa; Stephanie L Spear; Suzanne H Michel; Richard B Parad; Terry B White; Philip M Farrell; Bruce C Marshall; Frank J Accurso Journal: J Pediatr Date: 2009-12 Impact factor: 4.406
Authors: Don B Sanders; Aliza Fink; Nicole Mayer-Hamblett; Michael S Schechter; Gregory S Sawicki; Margaret Rosenfeld; Patrick A Flume; Wayne J Morgan Journal: J Pediatr Date: 2015-09-02 Impact factor: 4.406
Authors: Thida Ong; Frankline M Onchiri; Maria T Britto; Sonya L Heltshe; Larry G Kessler; Michael Seid; Bonnie W Ramsey Journal: J Cyst Fibros Date: 2021-08-26 Impact factor: 5.482
Authors: Scott C Bell; Marcus A Mall; Hector Gutierrez; Milan Macek; Susan Madge; Jane C Davies; Pierre-Régis Burgel; Elizabeth Tullis; Claudio Castaños; Carlo Castellani; Catherine A Byrnes; Fiona Cathcart; Sanjay H Chotirmall; Rebecca Cosgriff; Irmgard Eichler; Isabelle Fajac; Christopher H Goss; Pavel Drevinek; Philip M Farrell; Anna M Gravelle; Trudy Havermans; Nicole Mayer-Hamblett; Nataliya Kashirskaya; Eitan Kerem; Joseph L Mathew; Edward F McKone; Lutz Naehrlich; Samya Z Nasr; Gabriela R Oates; Ciaran O'Neill; Ulrike Pypops; Karen S Raraigh; Steven M Rowe; Kevin W Southern; Sheila Sivam; Anne L Stephenson; Marco Zampoli; Felix Ratjen Journal: Lancet Respir Med Date: 2019-09-27 Impact factor: 30.700
Authors: Catherine M McDonald; Jessica A Alvarez; Julianna Bailey; Ellen K Bowser; Kristen Farnham; Mark Mangus; Laura Padula; Kathleen Porco; Mary Rozga Journal: J Acad Nutr Diet Date: 2020-06-19 Impact factor: 5.234
Authors: Christina B Barreda; Philip M Farrell; Anita Laxova; Jens C Eickhoff; Andrew T Braun; Ryan J Coller; Michael J Rock Journal: J Cyst Fibros Date: 2020-06-13 Impact factor: 5.482
Authors: Tyler R Ray; Maja Ivanovic; Paul M Curtis; Daniel Franklin; Kerem Guventurk; William J Jeang; Joseph Chafetz; Hannah Gaertner; Grace Young; Steve Rebollo; Jeffrey B Model; Stephen P Lee; John Ciraldo; Jonathan T Reeder; Aurélie Hourlier-Fargette; Amay J Bandodkar; Jungil Choi; Alexander J Aranyosi; Roozbeh Ghaffari; Susanna A McColley; Shannon Haymond; John A Rogers Journal: Sci Transl Med Date: 2021-03-31 Impact factor: 17.956
Authors: Melissa A Wilk; Andrew T Braun; Philip M Farrell; Anita Laxova; Donna M Brown; James M Holt; Camille L Birch; Nadiya Sosonkina; Brandon M Wilk; Elizabeth A Worthey Journal: Cold Spring Harb Mol Case Stud Date: 2020-02-03